Silver Book Fact

The NEI-sponsored Age-Related Eye Disease Study (AREDS) found that individuals at high risk of developing advanced stages of age-related macular degeneration (AMD) lowered their risk of disease progression by about 25% when treated with the AREDS nutritional formula (daily, high-dose combination of vitamins C,E, beta-carotene, and zinc).

Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS report no. 8. Arch Opthalmol. 2001; 119(10): 1417-36. http://archopht.jamanetwork.com/article.aspx?articleid=268224

Reference

Title
A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS report no. 8
Publication
Arch Opthalmol
Publication Date
2001
Authors
Age-Related Eye Disease Study Research Group
Volume & Issue
Volume 119, Issue 10
Pages
1417-36
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Supplementation with lutein increases macular pigment optical density by 27%; which is correlated with benefits in visual function.  
  • Between 2008 and 2009, the number of Americans age 65-74 who reported trouble seeing (even with glasses or contacts) decreased from 14.3% to 10.3%.  The number of Americans age 75…  
  • The ACCORD Eye Study found that combination lipid therapy with a fibrate and statin (compared with statin treatment alone) reduced progression of diabetic retinopathy in type 2 diabetics by around…  
  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.  
  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.